Embecta Corp. EMBC revenue by segment, product and geography
In its fiscal year ending 2025-09-30, Embecta Corp. reported revenue across 5 products and services; the largest, Pen Needles, was $784M, 72.6% of the filed sum (-7.1% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Pen Needles$784M72.6%-7.1% yoy
- Safety$138M12.8%+6.5% yoy
- Syringes$125M11.5%-1.3% yoy
- Manufacturing Facility$19.9M1.8%+55.5% yoy
- Product And Service Other$14M1.3%+35.9% yoy
Members sum to the consolidated $1.08B for this period.
- United States$579M53.6%-4.6% yoy
- Outside the United States$501M46.4%-2.8% yoy
Members sum to the consolidated $1.08B for this period.
- Pen Needles$155M69.7%-17.8% yoy
- Safety$34.3M15.5%+0.3% yoy
- Syringes$26.3M11.9%-8.7% yoy
- Product And Service Other$4M1.8%+21.2% yoy
- Manufacturing Facility$2.5M1.1%-43.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.